TETRIS PHARMA LAUNCHES OGLUO® IN AUSTRIA

RNS Number : 5713L

Arecor Therapeutics PLC

04 January 2023

 

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

TETRIS PHARMA LAUNCHES OGLUO ® IN AUSTRIA

Cambridge, UK, 4 January 2023: Arecor Therapeutics plc (AIM: AREC),the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that subsidiary company, Tetris Pharma Ltd, has today launched Ogluo® (glucagon prefilled autoinjector pen) as a treatment for severe hypoglycaemia in children and adults living with diabetes in Austria, the second European launch in the Ogluo® European roll-out strategy.

See full Tetris Pharma announcement below:

Tetris Pharma European roll-out of Ogluo® continues with launch in Austria

A new treatment option for severe hypoglycaemia for children and adults living with diabetes

4 January 2023 - Tetris Pharma Ltd ("Tetris Pharma" or "the Company"), a subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC), today announces the launch of Ogluo® (glucagon prefilled autoinjector pen) in Austria as a treatment for severe hypoglycaemia in adults, adolescent, and children aged two years and over living with diabetes mellitus.

Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon to treat severe hypoglyceamia for people living with diabetes. There are an estimated 450,000 adults living with diabetes in Austria (IDF Atlas 10^th Edition).

Ogluo® pricing has been published in Austria in the Warenverzeichnis (the reference for all Austrian pharmacies, insurers and wholesalers) managed by the Apotheker-Verlages®. Full prescribing information can be found here . Today's launch in Austria builds on the roll-out of Ogluo® in Germany and Great Britain, as part of the pan-European commercialisation programme through which Tetris Pharma intends to commercialise Ogluo® in core European markets. The Company is currently in discussions with various health authorities across Europe to ensure timely launches in additional major European countries.

"In Austria, people living with diabetes will now be able to receive Ogluo® to tackle severe hypoglycaemic events, enabling patients and those around to them to act quickly when such an event happens," said Dr Shafiq Choudhary, Managing Director of Tetris Pharma, "With this launch in Austria, we look forward to expanding our reach within Europe over the coming months to bring this new treatment to people living with diabetes."

Enquiries:

Tetris Pharma

Shafiq Choudhary  [phone]

Notes to Editors

Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a commercial-stage specialty pharmaceutical company with expertise in registering, marketing, sales and the distribution of speciality hospital products across the UK and Europe. Our experienced team has a proven history of building and growing sales. Having secured distribution rights for already licensed products across Europe, we have a portfolio of niche injectable products including Ogluo^®, a ready-to-use glucagon for emergency use to treat hypoglycaemia. We collaborate with partners to provide patients with effective treatments and quality healthcare by ensuring we deliver accountability, partnership and performance.

For further information, please visit tetrispharma.com

-ENDS-

For more information, please contact:

Arecor Therapeutics plc	www.arecor.com
Dr Sarah Howell, Chief Executive Officer	Tel: [phone] Email: [e-mail]
Susan Lowther, Chief Financial Officer	Tel: [phone] Email: [e-mail]
Mo Noonan, Communications	Tel: [phone] Email: [e-mail]
Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking)	Tel: [phone]
Consilium Strategic Communications Chris Gardner, David Daley, Angela Gray	Tel: [phone] Email: [e-mail]

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform,Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. 

For further details please see our website, www.arecor.com

 

END

 

 

NRABJMRTMTJMBIJ